Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 709-715

  Conti, J A ^a   Kemeny, N E ^a   Saltz, L B ^a   Huang, Y ^a   Tong, W P ^a   Chou, T C ^a   Sun, M ^a   Pulliam, S ^a   Gonzalez, C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ATROPINE; DEXAMETHASONE; DIPHENHYDRAMINE; DNA TOPOISOMERASE; IRINOTECAN; LOPERAMIDE; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0029919598     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.709     Document Type: Article

References (54)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA 45:8-30, 1995
2. Hansen RM: Systemic therapy in metastatic colorectal cancer. Arch Intern Med 150:2265-2269, 1990
3. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
4. Wall ME, Wani MC, Cook CE, et al: A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890, 1966
5. Schneider E, Hsiang Y-H, Liu DF: DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149-183, 1990
6. Wang JC: DNA topoisomerases. Ann Rev Biochem 54:665-697, 1985
7. Hsiang YH, Likou M, Liu F: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
8. Hsiang Y-H, Liu LF, Hochster H, et al: Levels of DNA topoisomerase I and II in human colorectal carcinoma and normal colonic mucosa. Proc Am Assoc Cancer Res 29:172, 1988 (abstr)
9. Hirabayashi N, Kim R, Nishiyama M, et al: Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Proc Am Assoc Cancer Res 33:436, 1992 (abstr)
10. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972
11. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
12. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer xenografts. Science 246:1046-1048, 1989
13. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase-I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
14. Matsuzaki T, Yokohura T, Mutai M, et al: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308-312, 1988
15. Kawato Y, Furuta T, Aonuma M, et al: Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28:192-198, 1991
16. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecan derivative in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
17. Pitot HC, Wender D, O'Connell MJ, et al: A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group. Proc Am Soc Clin Oncol 13:197, 1994 (abstr)
18. Rothenberg ML, Eckardt JR, Burris HA III, et al: Irinotecan (CPT-11) as second-line therapy for pts with 5-FU-refractory colorectal cancer. Proc Am Soc Clin Oncol 13:198, 1994 (abstr)
19. Bugat R, Rougier P, Douillard JY, et al: Efficacy of irinotecan HCI (CPT-11) in patients with metastatic colorectal cancer after progression while receiving a 5FU-based chemotherapy. Proc Am Soc Clin Oncol 14:222, 1995 (abstr)
20. Karnofsky DA, Burchenal JH: Clinical evaluation of chemotherapeutic agents in cancer, in Macleod CM (ed): Evaluation of Chemotherapeutic Agents. Symposium, Microbiology Section, New York Academy of Medicine. New York, NY, Columbia University, 1949, pp 191-205
21. Culine S, de Forni M, Extra JM, et al: Phase I study of the camptothecin analog CPT-11 using a weekly schedule. Proc Am Assoc Clin Oncol 11:110, 1992 (abstr)
22. Creekmore SP, Urba WJ, Longo DL: Principles of the clinical evaluation of biologic agents, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 67-86
23. Kaneda N, Yokokura T: Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725, 1990
24. Tanizawa A, Pommier Y: Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52:1848-1854, 1992
25. Pommier Y, Kerrigan D, Schwartz R, et al: Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46:3075-3081, 1986
26. Liu L, Miller K: Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from Hela cell nuclei. Proc Natl Acad Sci USA 78:3487-3491, 1991
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
28. Kemeny N, Braun DW Jr: Prognostic factors in advanced colorectal carcinoma. Am J Med 74:786-794, 1983
29. Kemeny N, Niedzwiecki D, Shurgot B, et al: Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 63:742-747, 1989
30. Rothenberg ML, Kuhn JG, Burns HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
31. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20, 1992
32. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
33. Negora S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, a new camptothecin derivative, for small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:241, 1991 (abstr)
34. Ogawa M, Taguchi T: Clinical studies with CPT-11: The Japanese experience. Ann Oncol 3:118, 1992 (suppl 1, abstr)
35. Nishiroura G, Satou T, Yoshimitsu Y, et al: Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer. Jpn J Cancer Chemother 22:93-97, 1995
36. Moertel CG, Reitemeier RJ: Clinical features influencing therapeutic response to fluorinated pyrimidines, in Moertel CG, Reitemeier RJ (eds): Advanced Gastrointestinal Cancer/Clinical Management and Chemotherapy. New York, NY, Harper & Row, 1969, pp 122-125
37. Abigerges D, Chabot GG, Armand J-P, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
38. Abigerges D, Armand J-P, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
39. Kanzawa F, Kondoh H, Kwon S, et al: Role of carboxylesterase on metabolism of camptothecin analog (CPT-11) in non-small cell lung cancer cell line PC-7 cells. Proc Am Assoc Cancer Res 33:427, 1992 (abstr)
40. Kawato Y, Aonuma M, Hirata Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991
41. Investigators' Brochure: CPT-11, Cancer Chemotherapeutic Agent. Princeton, NJ, G.H. Besselaar, 1992
42. Slichenmeyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
43. Sasak Y, Yoshida Y, Sudah K, et al: Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86:111-116, 1995
44. Pommier Y, Leteurte F, Fesen MR, et al: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530-542, 1994
45. McLeod HL, Douglas F, Dates M, et al: Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 59:607-611, 1994
46. Kanzawa F, Sugimoto Y, Minato K, et al: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res 50:5919-5924, 1990
47. Sugimoto Y, Tsukahara S, Oh-hara T, et al: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50:6925-6930, 1990
48. Yamamuchi M, Nagai S, Ito A, et al: Treatment targeting DNA topoisomerase of human gastrointestinal cancer in xenografts. Proc Am Assoc Cancer Res 33:437, 1992 (abstr)
49. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565-5569, 1987
50. Kjeldsen E, Bonven BJ, Andoh T, et al: Characterization of a camptothecin-resistant human DNA topoisomerase I. J Biol Chem 263:3912-3916, 1988
51. Goldwasser F, Bae I, Valenti M, et al: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55:2116-2121, 1995
52. Shimada Y, Sasaki Y, Sugano K, et al: Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil in metastatic colorectal cancer. Proc Am Soc Clin Oncol 12:196, 1993 (abstr)
53. Sasaki Y, Ohtsu A, Shimada Y, Ono K, et al: Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 86:1096-1098, 1994 (letter)
54. Saltz L, Kanowitz J, Kemeny N, et al: Phase I trial of irinotecan (CPT-11), 5-fluorouracil, and leucovorin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 14:476, 1995 (abstr)